A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys

Journal of Medical Primatology

Volumn 26, Issue 1-2, 1997, Pages 51-58

  Cole, Kelly Stefano ^a   Rowles, Jennifer L ^a   Murphey Corb, Michael ^b   Clements, Janice E ^c   Robinson, James ^d   Montelaro, Ronald C ^a,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

AIDS vaccines; Antibody avidity; Conformational dependence; Neutralization; Serology

Indexed keywords

MACACA MULATTA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; IMMUNOLOGY; MACACA; SERODIAGNOSIS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; MACACA MULATTA; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0031064390     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0684.1997.tb00319.x     Document Type: Article

References (30)

1. ANDERSON MG, HAUER D, SHARMA DP, JOAG SV, NARAYAN O, ZINK MC, CLEMENTS JE: Analysis of envelope changes acquired by SIVmac239 during neuroadaptation in rhesus macaques. Virology 195:616-626, 1993.
2. BASKIN GB, MARTIN LN, RANGAN SRS, GORMUS BJ, MURPHEY-CORB M, WOLF RH, SOIKE KF: Transmissible lymphoma and simian acquired immunodeficiency syndrome in rhesus macaques. JNCI 77:127-139, 1986.
3. BERMAN PW, GREGORY TJ, RIDDLE I, NAKAMURA GR, CHANPE MA, PORTER JP, WURM FM, HERSHBERG RD, COBB EK, EICHBERG JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622-625, 1990.
4. CLEMENTS JE, MONTELARO RC, ZINK MC, AMADEE AM, MILLER S, TRICHEL AM, JAGERSKI B, HAUER D, MARTIN LN, BOHM RP, MURPHEY-CORB M: Cross-protective immune responses induced in rhesus macaques by immunization with an attenuated macrophage-tropic simian immunodeficiency virus. J Virol 69:2737-2744, 1995.
5. DANIEL MD, KIRCHHOFF F, CZAJAK SC, SEHGAL PK, DESROSIERS RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941, 1992.
6. DANIEL MD, MAZZARA GP, SIMON MA, SEHGAL PK, KODAMA T, PANICALI DL, DESROSIERS RC: High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses 10:839-851, 1994.
7. DESROSIERS RC: The simian immunodeficiency viruses. Ann Rev Immunol 8:557-578, 1990.
8. GARDNER M, ROSENTHAL A, JENNINGS M, YEE J, ANTIPA L, ROBINSOV E JR: Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 11:843-854, 1995.
9. GIRARD M, KIENY M-P, PINTER A, BARRE-SINOUSSI F, NARA P, KOLBE H, KUSUMI K, CHAPUT A, REINHART T, MUCHMORE E, RONCO J, GOMARD E, GLUCKMAN J-C, FULTZ PN: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 88:542-546, 1991.
10. HEDMAN K, HIETALA J, TIILIKAINEN A, HARTIKAINEN-SORRI A-L, RAIHA K, SUNI J, VAANENEN P, PIETILAINEN M: Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (avidity-ELISA) and by haemolysis typing. J Med Virol 27:293-298, 1989.
11. HEDMAN K, SEPPALA I: Recent rubella virus infection indicated by a low avidity of specific IgG. J Clin Immunol 8:214-221, 1988.
12. HIRSCH VM, FUERST TR, SUTTER G, CARROLL MW, YANG LC, GOLDSTEIN S, PIATAK M JR, ELKINS WR, ALVORD WG, MONTEFIORI DC: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effects of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70:3741-3752, 1996.
13. HOFMANN-LEHMANN R, HOLZNAGEL E, AUBERT A, OSSENT P, REINACHER M, LUTZ H: Recombinant FeLV vaccine: Long-term protection and effect on course and outcome of FIV infection. Vet Immunol Immunopathol 46:127-137, 1995.
14. HU S-L, ABRAMS K, BARBER GN, MORAN P, ZARLING JM, LANGLOIS AJ, KULLER L, MORTON WR, BENVENISTE RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459, 1992.
15. HULSKOTTE EG, GERETTI AM, SIEBELINK KH, VANAMEROGEN G, CRANAGE MP, RUD EW, NORLEY SG, DEVRIES P, OSTERHAUS AD: Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J Virol 69:6289-6296, 1995.
16. JAVAHERIAN K, LANGLOIS AJ, SCHMIDT S, KAUFMANN N, CATES N, LANGEDIJK JPM, MELOEN RH, DESROSIERS RC, BURNS DPW, BOLOGNESI DP, PUTNEY SD: The principal neutralizing determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus. Proc Natl Acad Sci USA 256:320, 1994.
17. KARBER G: Beitrag zue kollektiven Behandlung pharmakologischer Reinhenversuche. Arch Exp Pathol Pharmakol 162:480-487, 1931.
18. LEHNER T, WANG Y, CRANAGE M, MITCHELL E, TAO L, HALL G, DENNIS M, COOK N, BROOKES R, KLAVINSKIS L, JONES I, DOYLE C, WARD R: Protective mucosal immunity elicited by target iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2:767-775, 1996.
19. LOHMAN BL, MCCHESNEY MB, MILLER CJ, MCGOWAN E, JOYE SM, VANROMPAY KA, REAY E, ANTIPA L, PEDERSEN NC, MARTHAS ML: A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 68:7021-7029, 1994.
20. MEANS GE, FEENEY RE: Chemical Modifications of Proteins, San Francisco: Holden-Day, 1971, pp 216-222.
21. MONTEFIORI DC, REIMANN KA, LETVIN NL, ZHOL J, HU S-L: Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. AIDS Res Hum Retroviruses 11:963-970, 1995.
22. MOSSMAN SP, BEX F, BERGLUND P, ARTHOS J, O'NEIL SP, RILEY D, MAUL DH, BRUCK C, MOMIN P, BURNY A, FULTZ PN, MULLINS JI, LILJESTROM P, HOOVER EA: Protection against lethal simian immunodeficiency virus SIV-smmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by gp120 subunit vaccine. J Virol 70:1953-1960, 1996.
23. MURPHEY-CORB M, MARTIN IN, DAVIDSON-FAIRBURN B, MONTELARO RC, MILLER M, WEST M, OHKAWA S, BASKIN GB, ZHANG J-Y, PUTNEY SD, ALLISON AC, EPPSTEIN DA: A formalin-inactivated whole SIV vaccine confers protection in macaques. 246:1293-1297, 1989.
24. MURPHEY-CORB M, MONTELARO RC, MILLER MA, WEST M, MARTIN LN, DAVISON-FAIRBURN B, OHKAWA S, BASKIN GB, ZHANG J-Y, MILLER GB, PUTNEY SD, ALLISON AC, EPPSTEIN DA: Efficacy of SIV/DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS 5:655-662, 1991.
25. OHKAWA S, XU K, WILSON LA, MONTELARO RC, MARTIN LN, MURPHEY-CORB M: Analysis of envelope glycoprotein-specific antibodies from SIV-infected and gp110-immunized monkeys in ACC and ADCC assays. AIDS Res Hum Retroviruses 11:395-403, 1995.
26. SCHLIENGER K, MONTEFIORI DC, MANCINI M, RIVIERE Y, TIOLLAIS P, MICHAEL ML: Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol 68:6578-6588, 1994.
27. SHAFFERMAN A, LEWIS MG, MCCUTCHAN FE, BENVENISTE RE, JAHRLING PB, BURKE DS, EDDY GA: Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge. Vaccine 11:848-852, 1993.
28. SHARMA DP, ZINK MC, ANDERSON M, ADAMS R, CLEMENTS JE, JOAG SV, NARAYAN O: Derivation of neuotropic simian immunodeficiency virus from exclusively lymphocytetropic parental virus: Pathogenesis of infection in macaques. J Virol 66:3550-3556, 1992.
29. WARD KN, DHALIWAL W, ASHWORTH KL, CLUTTERBUCK EJ, TEO CG: Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J Med Virol 43:367-372, 1994.
30. WYAND MS, MANSON KH, GARCIA-MOLL M, MONTEFIORI D, DESROSIERS RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 70:3724-3733, 1996.